Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The United Laboratories International Holdings Limited (ULIHF)
OTHER OTC:ULIHF
ULIHF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.90 - $1.95
Previous CloseN/A
Volume13.00K
Average Volume (3M)147.00
Market Cap
$2.94B
Enterprise Value$9.80B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)7.2
Beta0.18
Next Earnings
Apr 01, 2025EPS Estimate
0.11Last Dividend Ex-Date
Sep 19, 2024Dividend Yield4.93%
Share Statistics
EPS (TTM)0.22
Shares Outstanding1,817,026,500
10 Day Avg. Volume0
30 Day Avg. Volume147
Standard Deviation0.15
R-Squared0.00709
Alpha0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.88
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1.93Price Target Upside17.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
The United Laboratories International Holdings News
PremiumCompany Announcements
The United Laboratories Unveils New Board and Committees
PremiumCompany Announcements
United Laboratories Gains Approval for Mupirocin Ointment
PremiumCompany Announcements
The United Laboratories Vests Over 3 Million Shares
PremiumCompany Announcements
United Laboratories’ Antibiotic Gains Key Approval
PremiumCompany Announcements
United Laboratories Acquires Award Shares Under Scheme
PremiumCompany Announcements
United Laboratories’ Antibiotic Product Gains Key Approval
PremiumCompany Announcements
United Laboratories’ Amoxicillin Granules Gain Key Approval---
Bulls Say, Bears Say
Bulls Say
Cost ManagementSelling costs were reduced by Rmb260mn to Rmb715mn, showing a significant year-over-year decrease.
Growth ProjectionsFurther growth is expected from finished drugs, including the soon-to-be-approved liraglutide generic, insulins, and animal drugs.
Product LaunchesAnimal drugs are on a strong growth track with new product launches.
Bears Say
Capacity ConcernsManagement does not see extra capacity coming online to pressure 6-APA prices, which might limit future supply flexibility.
Market ExpectationsStreet's estimate has already moved up by 6% since early July, suggesting expectations may be high and challenging to exceed.
Profit Outlook1H24 net profit was in line with estimates, but only slightly above consensus, indicating limited upside surprise.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
4.74% Mutual Funds
0.09% Other Institutional Investors
92.12% Public Companies and
Individual Investors
ULIHF FAQ
What was The United Laboratories International Holdings Limited’s price range in the past 12 months?
The United Laboratories International Holdings Limited lowest stock price was $0.90 and its highest was $1.95 in the past 12 months.
What is The United Laboratories International Holdings Limited’s market cap?
The United Laboratories International Holdings Limited’s market cap is $2.94B.
When is The United Laboratories International Holdings Limited’s upcoming earnings report date?
The United Laboratories International Holdings Limited’s upcoming earnings report date is Apr 01, 2025 which is in 38 days.
How were The United Laboratories International Holdings Limited’s earnings last quarter?
The United Laboratories International Holdings Limited released its earnings results on Aug 29, 2024. The company reported $0.113 earnings per share for the quarter, beating the consensus estimate of $0.105 by $0.008.
Is The United Laboratories International Holdings Limited overvalued?
According to Wall Street analysts The United Laboratories International Holdings Limited’s price is currently Undervalued.
Does The United Laboratories International Holdings Limited pay dividends?
The United Laboratories International Holdings Limited pays a Annually dividend of $0.023 which represents an annual dividend yield of 4.93%. See more information on The United Laboratories International Holdings Limited dividends here
What is The United Laboratories International Holdings Limited’s EPS estimate?
The United Laboratories International Holdings Limited’s EPS estimate is 0.11.
How many shares outstanding does The United Laboratories International Holdings Limited have?
The United Laboratories International Holdings Limited has 1,817,026,500 shares outstanding.
What happened to The United Laboratories International Holdings Limited’s price movement after its last earnings report?
The United Laboratories International Holdings Limited reported an EPS of $0.113 in its last earnings report, beating expectations of $0.105. Following the earnings report the stock price went up 4.545%.
Which hedge fund is a major shareholder of The United Laboratories International Holdings Limited?
Currently, no hedge funds are holding shares in ULIHF
---
The United Laboratories International Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.93 (17.68% Upside)
$1.93 (17.68% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
57.14%
12-Months-Change
Fundamentals
Return on Equity
23.34%
Trailing 12-Months
Asset Growth
15.43%
Trailing 12-Months
Company Description
The United Laboratories International Holdings Limited
United Laboratories International Holdings Ltd. operates as an investment company, which engages in the manufacturing and sale of medicines, and the bulk and intermediate products used to produce finished goods. It operates through the following segments: Intermediate Products, Bulk Medicine, and Finished Products. The Intermediate Products segment offers two major products, such as T-Octylammonium Clavulanate and 6-APA. The Bulk Medicine segment includes amoxicillin and insulin. The Finished Products segment includes the sale of antibiotics and non-antibiotics finished products, and capsule casings including Semi-synthetic penicillins antibiotics, Cephalosporins antibiotics, and Insulin products. The company was founded on March 6, 2006 and is headquartered in Hong Kong.
---
ULIHF Stock 12 Month Forecast
Average Price Target
$1.93
▲(17.68% Upside)
Technical Analysis
Ping An Insurance Company of China
―
Sino Biopharmaceutical
―
CSPC Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
Huazhu Group Ltd
―
Best Analysts Covering ULIHF
1 Year
Unknown AnalystJefferies
Not Ranked
1 Year Success Rate
0/0 ratings generated profit
1 Year Average Return
0.00%
reiterated a buy rating 4 months ago
Copying Unknown Analyst's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of 0.00% per trade.
---